Treatment Eligibility

KALYDECO® (ivacaftor) targets the underlying cause of CF in patients age 4 months and older who have ivacaftor-responsive CFTR mutations1

CFTR Mutations Responsive to KALYDECO
Based on Clinical and/or In Vitro Data1-3
A1067T G551D R1070Q
A455E G551S R1070W
D110E G1069R S549N
D110H G1244E S549R
D1152H G1349D S945L
D1270N K1060T S977F
D579G L206W S1251N
E56K P67L S1255P
E193K R74W 711+3A→G
E831X R117C 2789+5G→A
F1052V R117H 3272-26A→G
F1074L R347H 3849+10kbC→T
G178R R352Q  
CFTR Mutations Responsive to
KALYDECO Based on Clinical
and/or In Vitro Data1-3
A1067T G551D R1070Q
A455E G551S R1070W
D110E G1069R S549N
D110H G1244E S549R
D1152H G1349D S945L
D1270N K1060T S977F
D579G L206W S1251N
E56K P67L S1255P
E193K R74W 711+3A→G
E831X R117C 2789+5G→A
F1052V R117H 3272-26A→G
F1074L R347H 3849+10kbC→T
G178R R352Q  
  • CFTR mutations with clinical and in vitro data 
  • CFTR mutations with in vitro data only
  • CFTR mutations with clinical data only 

F508del and 26 other mutations are considered not responsive to ivacaftor (see full Prescribing Information for complete listing).1

 

Back to top